NO20041180L - Pyrrolopyrimidiner som midler for inbibering av cysteinprotaser - Google Patents

Pyrrolopyrimidiner som midler for inbibering av cysteinprotaser

Info

Publication number
NO20041180L
NO20041180L NO20041180A NO20041180A NO20041180L NO 20041180 L NO20041180 L NO 20041180L NO 20041180 A NO20041180 A NO 20041180A NO 20041180 A NO20041180 A NO 20041180A NO 20041180 L NO20041180 L NO 20041180L
Authority
NO
Norway
Prior art keywords
pyrrolopyrimidines
inhibition
agents
cysteine proteases
proteases
Prior art date
Application number
NO20041180A
Other languages
English (en)
Other versions
NO328890B1 (no
Inventor
Martin Missbach
Naoki Teno
Kenji Hayakawa
Genji Iwasaki
Claudia Betschart
Osamu Irie
Junichi Sakaki
Rene Lattmann
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of NO20041180L publication Critical patent/NO20041180L/no
Publication of NO328890B1 publication Critical patent/NO328890B1/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Oncology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Transplantation (AREA)
  • Biomedical Technology (AREA)
  • Communicable Diseases (AREA)
  • Neurosurgery (AREA)
  • Hematology (AREA)
  • Pulmonology (AREA)
  • Neurology (AREA)
  • Pain & Pain Management (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
NO20041180A 2001-08-30 2004-03-19 Pyrrolopyrimidiner, anvendelse derav og farmasoytisk sammensetning omfattende en slik forbindelse NO328890B1 (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0121033.5A GB0121033D0 (en) 2001-08-30 2001-08-30 Organic compounds
PCT/EP2002/009663 WO2003020721A1 (en) 2001-08-30 2002-08-29 Pyrrolo pyrimidines as agents for the inhibition of cystein proteases

Publications (2)

Publication Number Publication Date
NO20041180L true NO20041180L (no) 2004-03-19
NO328890B1 NO328890B1 (no) 2010-06-07

Family

ID=9921234

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20041180A NO328890B1 (no) 2001-08-30 2004-03-19 Pyrrolopyrimidiner, anvendelse derav og farmasoytisk sammensetning omfattende en slik forbindelse

Country Status (29)

Country Link
US (2) US7452886B2 (no)
EP (1) EP1423391B8 (no)
JP (1) JP4629334B2 (no)
KR (1) KR100695845B1 (no)
CN (1) CN100372849C (no)
AR (1) AR036374A1 (no)
AT (1) ATE326469T1 (no)
AU (1) AU2002333760B2 (no)
BR (1) BR0212226A (no)
CA (1) CA2458684C (no)
CY (1) CY1105573T1 (no)
DE (1) DE60211530T2 (no)
DK (1) DK1423391T3 (no)
EC (1) ECSP044998A (no)
ES (1) ES2262888T3 (no)
GB (1) GB0121033D0 (no)
HU (1) HUP0401301A3 (no)
IL (3) IL160367A0 (no)
MX (1) MXPA04001935A (no)
MY (1) MY157368A (no)
NO (1) NO328890B1 (no)
NZ (1) NZ531343A (no)
PE (1) PE20030418A1 (no)
PL (1) PL368280A1 (no)
PT (1) PT1423391E (no)
RU (1) RU2331644C2 (no)
TW (1) TWI297690B (no)
WO (1) WO2003020721A1 (no)
ZA (1) ZA200401042B (no)

Families Citing this family (70)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030144234A1 (en) * 2001-08-30 2003-07-31 Buxton Francis Paul Methods for the treatment of chronic pain and compositions therefor
SE0201980D0 (sv) 2002-06-24 2002-06-24 Astrazeneca Ab Novel compounds
GB0220187D0 (en) * 2002-08-30 2002-10-09 Novartis Ag Organic compounds
MXPA05003254A (es) 2002-09-24 2005-06-08 Novartis Ag Agonistas del receptor de esfingosina-1-fosfato en el tratamiento de trastornos de desmielinacion.
AR043692A1 (es) * 2003-02-06 2005-08-10 Novartis Ag 2-cianopirrolopirimidinas y sus usos farmaceuticos
GB0304640D0 (en) * 2003-02-28 2003-04-02 Novartis Ag Organic compounds
JP4710606B2 (ja) * 2003-04-18 2011-06-29 小野薬品工業株式会社 スピロピペリジン化合物およびその医薬用途
BRPI0409868A (pt) * 2003-04-28 2006-05-16 Novartis Ag composição farmacêutica que compreende um inibidor da catepsina s e um opióide
EP1797883A3 (en) * 2003-04-28 2007-08-01 Novartis AG Pharmaceutical composition comprising a cathepsin S inhibitor and an opioid
UA82875C2 (en) * 2003-04-30 2008-05-26 Insecticidal (dihalopropenyl) phenylalkyl substituted dihydrobenzofuran and dihydrobenzopyran derivatives and method for controlling insects
WO2005011703A1 (en) * 2003-08-04 2005-02-10 Akzo Nobel N.V. 2-cyano-1,3,5-triazine-4,6-diamine derivatives
EP1786816A4 (en) 2003-09-10 2009-11-04 Virochem Pharma Inc SPIROHYDANTOIN COMPOUNDS AND METHODS FOR MODULATING CHEMOKINE RECEPTOR ACTIVITY
CN101845023A (zh) 2004-02-18 2010-09-29 阿斯利康(瑞典)有限公司 四唑化合物及其作为代谢型谷氨酸受体拮抗剂的应用
JPWO2005085210A1 (ja) * 2004-03-10 2008-01-17 小野薬品工業株式会社 ニトリル化合物およびその化合物を有効成分として含有する医薬組成物
ES2251292B1 (es) * 2004-04-20 2007-07-01 Inke, S.A. Procedimiento para la obtencion de un compuesto farmaceuticamente activo y de sus intermedios de sintesis.
WO2005111042A1 (en) * 2004-05-03 2005-11-24 Janssen Pharmaceutica N.V. Novel indole derivatives as selective androgen receptor modulators (sarms)
TW200614993A (en) 2004-06-11 2006-05-16 Akzo Nobel Nv 4-phenyl-pyrimidine-2-carbonitrile derivatives
JP5135795B2 (ja) 2004-08-27 2013-02-06 小野薬品工業株式会社 塩基性基を含有する化合物およびその用途
KR100651849B1 (ko) * 2005-02-01 2006-12-01 엘지전자 주식회사 세탁기
AU2006277678B2 (en) * 2005-08-05 2012-04-19 Hybrigenics Sa Novel cysteine protease inhibitors and their therapeutic applications
JP2009507003A (ja) 2005-09-01 2009-02-19 アレス トレーディング ソシエテ アノニム 視神経炎の治療
TW200745055A (en) * 2005-09-23 2007-12-16 Organon Nv 4-Phenyl-6-substituted-pyrimidine-2-carbonitrile derivatives
US7326715B2 (en) 2005-09-23 2008-02-05 N.V. Organon 4-Phenyl-6-substituted-pyrimidine-2-carbonitrile derivatives
AR056720A1 (es) * 2005-10-26 2007-10-17 Smithkline Beecham Corp Compuesto de tiazol substtuido composicion farmaceuticamente que lo comprende y su uso para preparar un medicamento
EP1961744B1 (en) 2005-11-18 2013-04-17 Ono Pharmaceutical Co., Ltd. Basic group-containing compound and use thereof
AU2006322060A1 (en) * 2005-12-05 2007-06-14 Incyte Corporation Lactam compounds and methods of using the same
US7687515B2 (en) 2006-01-17 2010-03-30 N.V. Organon 6-phenyl-1H-imidazo[4,5-c]pyridine-4-carbonitrile derivatives
JP5257068B2 (ja) 2006-05-16 2013-08-07 小野薬品工業株式会社 保護されていてもよい酸性基を含有する化合物およびその用途
EP2061775A2 (en) 2006-09-13 2009-05-27 Astra Zeneca AB Spiro-oxazolidinone compounds and their use as metabotropic glutamate receptor potentiators
US7932251B2 (en) 2007-07-16 2011-04-26 N.V. Organon 6-phenyl-1H-imidazo[4,5-c]pyridine-4-carbonitrile derivatives
TW200911803A (en) * 2007-07-16 2009-03-16 Organon Nv 6-phenyl-1H-imidazo [4,5-c] pyridine-4-carbonitrile derivatives
UY31403A1 (es) 2007-10-19 2009-05-29 "derivados novedosos de ({((3-metilfenil)-2h-tetrazol-5-il)-etoxi} -4h-1,2,4-triazol-3-il), composiciones farmacéuticas conteniendolos y uso médico de los mismos".
KR20180017232A (ko) 2008-06-20 2018-02-20 노파르티스 아게 다발성 경화증을 치료하기 위한 소아용 조성물
TW201035094A (en) 2009-01-16 2010-10-01 Organon Nv 6-phenyl-1H-imidazo[4,5-c]pyridine-4-carbonitrile derivatives
US8026236B2 (en) 2009-01-16 2011-09-27 N.V. Organon 6-phenyl-1H-imidazo[4,5-c]pyridine-4-carbonitrile derivatives
EP2845856A1 (en) 2009-06-29 2015-03-11 Incyte Corporation Pyrimidinones as PI3K inhibitors
US8759359B2 (en) 2009-12-18 2014-06-24 Incyte Corporation Substituted heteroaryl fused derivatives as PI3K inhibitors
AU2010339444A1 (en) 2009-12-30 2012-07-19 Arqule, Inc. Substituted pyrrolo-aminopyrimidine compounds
US9115126B2 (en) 2010-01-15 2015-08-25 Merck Sharp & Dohme B.V. 1H-[1,2,3]triazolo[4,5-c]pyridine-4-carbonitrile derivatives
EP2558463A1 (en) 2010-04-14 2013-02-20 Incyte Corporation Fused derivatives as i3 inhibitors
WO2011163195A1 (en) 2010-06-21 2011-12-29 Incyte Corporation Fused pyrrole derivatives as pi3k inhibitors
WO2012027495A1 (en) 2010-08-27 2012-03-01 University Of The Pacific Piperazinylpyrimidine analogues as protein kinase inhibitors
DK3091085T3 (da) 2010-10-06 2019-05-06 Inst Catalana Recerca Estudis Avancats Fremgangsmåde til at designe en terapi mod brystcancermetastase
TW201249844A (en) 2010-12-20 2012-12-16 Incyte Corp N-(1-(substituted-phenyl)ethyl)-9H-purin-6-amines as PI3K inhibitors
WO2012125629A1 (en) 2011-03-14 2012-09-20 Incyte Corporation Substituted diamino-pyrimidine and diamino-pyridine derivatives as pi3k inhibitors
US9126948B2 (en) 2011-03-25 2015-09-08 Incyte Holdings Corporation Pyrimidine-4,6-diamine derivatives as PI3K inhibitors
UA121539C2 (uk) 2011-09-02 2020-06-25 Інсайт Холдинґс Корпорейшн Гетероцикліламіни як інгібітори рі3к
AR090548A1 (es) 2012-04-02 2014-11-19 Incyte Corp Azaheterociclobencilaminas biciclicas como inhibidores de pi3k
EP2650682A1 (en) 2012-04-09 2013-10-16 Fundació Privada Institut de Recerca Biomèdica Method for the prognosis and treatment of cancer metastasis
CN104284895B (zh) * 2012-04-17 2016-08-31 安斯泰来制药株式会社 含氮双环式芳香族杂环化合物
BR112014030750A2 (pt) 2012-06-06 2017-08-22 Inst Catalana Recerca Estudis Avancats Método para diagnóstico, prognóstico e tratamento da metástase do câncer pulmonar
US10119171B2 (en) 2012-10-12 2018-11-06 Inbiomotion S.L. Method for the diagnosis, prognosis and treatment of prostate cancer metastasis
ES2906586T3 (es) 2012-10-12 2022-04-19 Inbiomotion Sl Método para el diagnóstico, pronóstico y tratamiento de metástasis de cáncer de próstata
KR20150122731A (ko) 2013-03-15 2015-11-02 펀다시오 인스티튜트 드 르세르카 바이오메디카 (아이알비 바르셀로나) 암 전이의 예후 및 치료 방법
WO2014184679A2 (en) 2013-03-15 2014-11-20 Inbiomotion S.L. Method for the prognosis and treatment of renal cell carcinoma metastasis
AU2014333513B2 (en) 2013-10-09 2020-11-26 Fundacio Institut De Recerca Biomedica (Irb Barcelona) Method for the prognosis and treatment of metastasizing cancer of the bone originating from breast cancer
US10077277B2 (en) 2014-06-11 2018-09-18 Incyte Corporation Bicyclic heteroarylaminoalkyl phenyl derivatives as PI3K inhibitors
EP3229909B1 (en) 2014-12-11 2020-10-14 Inbiomotion S.L. Binding members for human c-maf
UA122332C2 (uk) 2015-02-27 2020-10-26 Інсайт Корпорейшн Солі інгібітора pi3k і способи їх отримання
WO2016183060A1 (en) 2015-05-11 2016-11-17 Incyte Corporation Process for the synthesis of a phosphoinositide 3-kinase inhibitor
WO2016183063A1 (en) 2015-05-11 2016-11-17 Incyte Corporation Crystalline forms of a pi3k inhibitor
MX2018014279A (es) 2016-05-25 2019-07-08 Inbiomotion Sl Tratamiento terapeutico de cancer de mama con base en estado de c-maf.
US11654153B2 (en) 2017-11-22 2023-05-23 Inbiomotion S.L. Therapeutic treatment of breast cancer based on c-MAF status
KR102054910B1 (ko) * 2017-12-19 2019-12-12 한림제약(주) 피롤로[2,3-d]피리미딘 유도체 또는 이의 염 및 이를 포함하는 약학 조성물
WO2019204354A1 (en) 2018-04-16 2019-10-24 C4 Therapeutics, Inc. Spirocyclic compounds
EP3556760A1 (en) * 2018-04-19 2019-10-23 F. Hoffmann-La Roche AG Spiro compounds
MX2020012826A (es) 2018-06-01 2021-03-09 Incyte Corp Regimen de dosificacion para el tratamiento de trastornos relacionados con fosfatidilinositol 3-cinasas (pi3k).
AU2020250933A1 (en) 2019-04-05 2021-10-28 Centre Hospitalier Régional Et Universitaire De Brest Protease-activated receptor-2 inhibitors for the treatment of sensory neuropathy induced by a marine neurotoxic poisoning
WO2022226166A1 (en) * 2021-04-22 2022-10-27 Protego Biopharma, Inc. Spirocyclic imidazolidinones and imidazolidinediones for treatment of light chain amyloidosis
CN118284609A (zh) * 2021-12-01 2024-07-02 St制药株式会社 用于制备三唑并嘧啶酮衍生物的方法

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL270922A (no) * 1960-11-02
CH627919A5 (de) 1977-04-14 1982-02-15 Ciba Geigy Ag Herbizide mittel.
US5958930A (en) * 1991-04-08 1999-09-28 Duquesne University Of The Holy Ghost Pyrrolo pyrimidine and furo pyrimidine derivatives
DE59500788D1 (de) * 1994-05-03 1997-11-20 Ciba Geigy Ag Pyrrolopyrimidinderivate mit antiproliferativer Wirkung
US5683999A (en) * 1995-03-17 1997-11-04 The Dupont Merck Pharmaceutical Company Cyclic urea HIV protease inhibitors
EP0831829B1 (en) * 1995-06-07 2003-08-20 Pfizer Inc. Heterocyclic ring-fused pyrimidine derivatives
TR199902301T2 (xx) * 1997-03-19 1999-12-21 Basf Aktiengesellschaft Pirilo $2,3D]pirimidinler ve onlar�n kullan�m�.
WO2000000201A1 (en) * 1998-06-30 2000-01-06 Eli Lilly And Company BICYCLIC sPLA2 INHIBITORS
HK1039326A1 (zh) * 1998-09-18 2002-04-19 Abbott Gmbh & Co. Kg 4氨基吡咯并嘧啶作为激酶抑制剂
EA006227B1 (ru) * 1999-12-10 2005-10-27 Пфайзер Продактс Инк. СОЕДИНЕНИЯ ПИРРОЛО[2,3-d]ПИРИМИДИНА
WO2001070743A1 (en) * 2000-03-20 2001-09-27 Axys Pharmaceuticals, Inc. Non-amidine containing protease inhibitors
KR100711042B1 (ko) 2000-04-28 2007-04-24 다나베 세이야꾸 가부시키가이샤 환상 화합물

Also Published As

Publication number Publication date
PT1423391E (pt) 2006-09-29
NZ531343A (en) 2006-01-27
ZA200401042B (en) 2004-10-25
JP2005502683A (ja) 2005-01-27
ES2262888T3 (es) 2006-12-01
CN1549817A (zh) 2004-11-24
PL368280A1 (en) 2005-03-21
GB0121033D0 (en) 2001-10-24
NO328890B1 (no) 2010-06-07
CA2458684C (en) 2009-04-07
US20050054851A1 (en) 2005-03-10
AR036374A1 (es) 2004-09-01
CY1105573T1 (el) 2010-07-28
CA2458684A1 (en) 2003-03-13
MXPA04001935A (es) 2004-06-15
EP1423391A1 (en) 2004-06-02
DE60211530D1 (de) 2006-06-22
IL198643A (en) 2010-12-30
AU2002333760B2 (en) 2007-01-04
MY157368A (en) 2016-06-15
TWI297690B (en) 2008-06-11
KR20040029123A (ko) 2004-04-03
EP1423391B1 (en) 2006-05-17
PE20030418A1 (es) 2003-06-12
US7452886B2 (en) 2008-11-18
IL160367A (en) 2009-12-24
CN100372849C (zh) 2008-03-05
IL160367A0 (en) 2004-07-25
DK1423391T3 (da) 2006-09-25
HUP0401301A3 (en) 2008-03-28
EP1423391B8 (en) 2007-12-12
BR0212226A (pt) 2004-08-17
ATE326469T1 (de) 2006-06-15
RU2331644C2 (ru) 2008-08-20
WO2003020721A1 (en) 2003-03-13
HK1072254A1 (zh) 2005-08-19
KR100695845B1 (ko) 2007-03-20
HUP0401301A2 (hu) 2004-10-28
RU2004109815A (ru) 2005-10-20
ECSP044998A (es) 2004-04-28
DE60211530T2 (de) 2006-12-21
JP4629334B2 (ja) 2011-02-09
US20090054467A1 (en) 2009-02-26

Similar Documents

Publication Publication Date Title
DK1423391T3 (da) Pyrrolopyrimidiner som midler til inhibering af cysteinproteaser
NO20031065D0 (no) Spiroheterocykliske nitriler nyttige som reversible inhibitorer av cysteinproteaser
NO20033399L (no) Eterderivater anvendelige som inhibitorer av PDE4-isoenzymer
NO20033593L (no) Kinazoliner som MMP-13 inhibitorer
EP1272467A4 (en) Cathepsin cysteine protease inhibitors
NO20043158L (no) Substituerte kinazolinderivater som inhibitorer av aurorakinaser
NO20033618L (no) Ftalayinon-piperidino-derivater som PDE-4-inhibitorer
DK1372737T3 (da) Præparat til restenoseprofylakse
NO20023828L (no) Pyrimidin-4-on derivater som LDL-PLA2 inhibitorer
NO20035087D0 (no) Anvendelse av HMG fragment som anti-inflammatoriske midler
NO20040084L (no) Peptid-baserte forbindelser
NO20035728L (no) Pyrrolopyrimidiner som proteinkinaseinhibitorer
AU2002340031A1 (en) Compounds useful as reversible inhibitors of cysteine proteases
DK1442030T3 (da) Thiopen- og thiazolsulfonamider som antineoplastiske midler
DK1458447T3 (da) Kombination af cytokrom-p450-beroende proteasinhibitorer
FI20010558L (fi) Kappaleiden paikannus
DE60229764D1 (de) Entgratwerkzeug
NO20041968L (no) Anvendelse av cystationin
NO20033234L (no) Karotenoider som antihypertensjonsmidler
ATE330603T1 (de) Benzothiazolderivaten
NO20042057L (no) Fosfonsyreforbindelser som inhibitorer av serinproteaser
AU2002242500A1 (en) Cathepsin cysteine protease inhibitors
NO20030820L (no) Anvendelse av vitamin D derivater som benresorpsjons inhibitorer
EP1450810A4 (en) XANTHINE INHIBITION
AU2001253633A1 (en) Inhibitors of the ice/ced-3 family of cysteine proteases

Legal Events

Date Code Title Description
MM1K Lapsed by not paying the annual fees